Uso do eculizumab na síndrome hemolítica urêmica atípica: relato de caso e revisão da literatura

Vaisbich, Maria Helena; Henriques, Luciana dos Santos; Watanabe, Andréia; Pereira, Lilian Monteiro; Metran, Camila Cardoso; Malheiros, Denise Avancini; Modanez, Flávia; Silva, João Domingos Montoni da; Vieira, Simone; Macedo, Ana Catarina Lunz; Massarope, Bianca; Furusawa, Érika Arai; Schvartsman, Benita Galassi Soares.
J. bras. nefrol ; 35(3): 237-241, jul.-set. 2013. ilus, tab
Artículo en Portugués | LILACS | ID: lil-687826

Documentos relacionados

  1. [Eculizumab for the treatment of atypical hemolytic uremic syndrome: case report and revision of the literature].
  2. [Hemolytic uremic syndrome].
  3. Typical or Atypical Hemolytic Uremic Syndrome and the Use of Eculizumab: 4 Illustrative Cases.
  4. Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab.
  5. Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome.
  6. A novel Shiga toxin 2a neutralizing antibody therapeutic with low immunogenicity and high efficacy.
  7. [A case of atypical hemolytic uremic syndrome successfully weaned from plasma exchange by treatment with eculizumab].
  8. Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome.
  9. Fenoldopam and renal hemodynamics in shiga toxin-related hemolytic uremic syndrome.
  10. HUS with mutations in CFH and STEC infection treated with eculizumab in a 4-year-old girl.